{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:55:47Z","timestamp":1784897747880,"version":"3.55.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":657,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["175095"],"award-info":[{"award-number":["175095"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds de Recherche Sant\u00e9 Quebec"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["175095"],"award-info":[{"award-number":["175095"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study aimed to evaluate the bidirectional relationship between kidney and cardiovascular (CV) events in trial participants with type 2 diabetes and CV disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Post hoc analyses of EMPA-REG OUTCOME using Cox regression models were performed to assess the association of baseline factors with risk of a kidney event and bidirectional associations of incident kidney events and CV events. Among placebo-treated participants, baseline factors significantly associated with greater kidney event risk included lower baseline estimated glomerular filtration rate, albuminuria, higher uric acid, low-density lipoprotein cholesterol levels, and prior heart failure (HF). Coronary artery disease was not associated with increased risk. In placebo-treated participants, occurrence of an incident non-fatal kidney event increased the subsequent risk of hospitalization for HF (HHF) but not 3-point major adverse CV events (non-fatal stroke, non-fatal myocardial infarction, and CV death). Vice versa, HHF (but not myocardial infarction\/stroke) increased the risk of subsequent kidney events. These associations were generally also seen in empagliflozin-treated participants and in the overall population. Interestingly, the risk of kidney events following HHF was not significantly increased in the relatively small number of placebo-treated participants already diagnosed with HF at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate a bidirectional inter-relationship between HHF and kidney events. Further exploration of this relationship and strategies to optimize the use of therapies to reduce both kidney and HF outcomes is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14601","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:53:31Z","timestamp":1703811211000},"page":"737-747","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Kidney and Heart Failure Events are Bidirectionally Associated in Patients with Type 2 Diabetes and Cardiovascular Disease"],"prefix":"10.1093","volume":"11","author":[{"given":"Abhinav","family":"Sharma","sequence":"first","affiliation":[{"name":"Division of Cardiology, McGill University Health Centre , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Testani","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Pernille","family":"Ofstad","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Norway KS , Asker ,","place":["Norway"]},{"name":"Oslo Diabetes Research Center , Oslo ,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fitchett","sequence":"additional","affiliation":[{"name":"St. Michael's Hospital, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Mattheus","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co KG , Ingelheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"St. Michael's Hospital, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques Plurith\u00e9matique 1433 , Nancy ,","place":["France"]},{"name":"INSERM 1116, CHRU de Nancy, FCRIN INI-CRCT , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina J.","family":"Kraus","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg , W\u00fcrzburg ,","place":["Germany"]},{"name":"Boehringer Ingelheim International GmbH , Ingelheim ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"2026012113155697000_ehf214601-bib-0001","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory\u2014A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012113155697000_ehf214601-bib-0002","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2026012113155697000_ehf214601-bib-0003","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2026012113155697000_ehf214601-bib-0004","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012113155697000_ehf214601-bib-0005","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/j.ackd.2014.03.003","article-title":"Cardiovascular complications of diabetic kidney disease","volume":"21","author":"P\u00e1lsson","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026012113155697000_ehf214601-bib-0006","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026012113155697000_ehf214601-bib-0007","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004646","article-title":"Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: Insights from the Get With The Guidelines\u2013Heart Failure Registry","volume":"11","author":"Sharma","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012113155697000_ehf214601-bib-0008","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/j.jacc.2005.11.084","article-title":"Renal impairment and outcomes in heart failure: Systematic review and meta-analysis","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012113155697000_ehf214601-bib-0009","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12149-013-0739-z","article-title":"Impaired renal function is a major determinant of left ventricular diastolic dysfunction: Assessment by stress myocardial perfusion imaging","volume":"27","author":"Sato","year":"2013","journal-title":"Ann Nucl Med"},{"key":"2026012113155697000_ehf214601-bib-0010","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113155697000_ehf214601-bib-0011","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.amjcard.2009.12.016","article-title":"Influence of renal function on the use of guideline-recommended therapies for patients with heart failure","volume":"105","author":"Heywood","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026012113155697000_ehf214601-bib-0012","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1161\/CIRCULATIONAHA.119.041022","article-title":"Impact of regulatory guidance on evaluating cardiovascular risk of new glucose-lowering therapies to treat type 2 diabetes mellitus: Lessons learned and future directions","volume":"141","author":"Sharma","year":"2020","journal-title":"Circulation"},{"key":"2026012113155697000_ehf214601-bib-0013","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/dom.14283","article-title":"Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM) in patients in the ACCORD trial","volume":"23","author":"Elharram","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2026012113155697000_ehf214601-bib-0014","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.ekir.2020.06.031","article-title":"Systematic review of the association between worsening renal function and mortality in patients with acute decompensated heart failure","volume":"5","author":"Yamada","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026012113155697000_ehf214601-bib-0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2459\/JCM.0000000000000974","article-title":"Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: A prognosis study","volume":"21","author":"Pugliese","year":"2020","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026012113155697000_ehf214601-bib-0016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12916-020-01616-8","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes: A renal function stratified analysis of the EXAMINE trial","volume":"18","author":"Ferreira","year":"2020","journal-title":"BMC Med"},{"key":"2026012113155697000_ehf214601-bib-0017","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","article-title":"Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: Implications for future interventions","volume":"118","author":"Pugliese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026012113155697000_ehf214601-bib-0018","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJMc1611290","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012113155697000_ehf214601-bib-0019","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012113155697000_ehf214601-bib-0020","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113155697000_ehf214601-bib-0021","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026012113155697000_ehf214601-bib-0022","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113155697000_ehf214601-bib-0023","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: Results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2026012113155697000_ehf214601-bib-0024","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004029","article-title":"Long-term evolution of renal function in patients with type 2 diabetes mellitus: A registry-based retrospective cohort study","volume":"3","author":"Goderis","year":"2013","journal-title":"BMJ Open"},{"key":"2026012113155697000_ehf214601-bib-0025","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/dc17-1091","article-title":"Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: Insights from the TECOS trial","volume":"40","author":"Sharma","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012113155697000_ehf214601-bib-0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100739","article-title":"Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years","volume":"32","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2026012113155697000_ehf214601-bib-0027","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026012113155697000_ehf214601-bib-0028","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1210\/clinem\/dgaa321","article-title":"Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial","volume":"105","author":"Inzucchi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026012113155697000_ehf214601-bib-0029","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: A contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026012113155697000_ehf214601-bib-0030","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.kint.2019.02.022","article-title":"Heart failure in chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"House","year":"2019","journal-title":"Kidney Int"},{"key":"2026012113155697000_ehf214601-bib-0031","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ehjci\/jeac254","article-title":"The incremental value of multi-organ assessment of congestion using ultrasound in outpatients with heart failure","volume":"24","author":"Pugliese","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012113155697000_ehf214601-bib-0032","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","article-title":"The use of diuretics in heart failure with congestion\u2014A position statement from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Mullens","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113155697000_ehf214601-bib-0033","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113155697000_ehf214601-bib-0034","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1681\/ASN.V1071606","article-title":"The clinical epidemiology of cardiac disease in chronic renal failure","volume":"10","author":"Parfrey","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2026012113155697000_ehf214601-bib-0035","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCULATIONAHA.119.043916","article-title":"Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment","volume":"141","author":"Bajaj","year":"2020","journal-title":"Circulation"},{"key":"2026012113155697000_ehf214601-bib-0036","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012113155697000_ehf214601-bib-0037","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.kint.2020.06.032","article-title":"A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death","volume":"99","author":"Ikizler","year":"2021","journal-title":"Kidney Int"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/737\/64540425\/eschf_11_2_737.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/737\/64540425\/eschf_11_2_737.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:17:59Z","timestamp":1769019479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/2\/737\/8271351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,28]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14601","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,12,28]]},"assertion":[{"value":"2023-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}